Galectin Therapeutics has reported a net loss of $2.54m, or $0.72 per share, for the second quarter ended on 30 June 2013 compared to a net loss of $2.66m, or $0.19 per share, in 2012.
Total operating loss for the second quarter ended 30 June 2013 was $2.55m compared to a total operating loss of $2.67m for the second quarter ended 30 June 2012.
The company has reported a net loss of $5.75m, or $0.94 per share, for the first half of 2013 compared to a net loss of $4.61m, or $0.36 per share, for the first half of 2012.
Total operating loss for the first six months of 2013 was $5.75m compared to a total operating loss of $4.62m for the first six months of 2012.
Galectin chief executive officer, president and chief medical officer Peter Traber said, "This first-in-man study will evaluate the safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis, and we expect top line clinical results for Phase 1 sometime late in 2013 or early 2014."
